Annexon Biosciences

Dr. Keswani is EVP & Chief Medical Officer of Annexon Biosciences, a position he has held since June 2019. He is an accomplished physician-scientist with broad R&D expertise in multiple therapeutic areas and is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Dr. Keswani has held senior executive positions in the pharmaceutical industry, including Roche, where he was Senior Vice President and Global Head of Neuroscience, Ophthalmology and Rare Diseases Research and Early Development. During his tenure at Roche, his group successfully advanced five molecules to Phase 3 development. Prior to Roche, he was Vice President, Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. He also held R&D leadership roles at Eli Lilly & Co. and Amgen, Inc. where he prosecuted the development of the now-approved CGRP antibodies for migraine prevention, Emgality and Aimovig. Dr. Keswani completed his residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins, where he cared for patients with diverse neurological diseases and ran a R01-funded neuroimmunology research lab. He graduated in medicine at St. Bartholomew’s Hospital and holds an Honors BSc degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences (Immunology).